ArticleClinical transplantation
Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study.
Article in Clinical transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 190 citations in OpenAlex.
- Management of obesity in kidney transplant candidates and recipients: A clinical practice guideline by the DESCARTES Working Group of ERA.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021Guideline
- Systematic review of drug bioavailability following gastrointestinal surgery.European journal of clinical pharmacology · 2018Pooled it
- Pharmacokinetic Profiles of Lansoprazole in Patients With Morbid Obesity Post-Roux-en-Y Gastric Bypass Surgery.Clinical and translational science · 2025Trial
- The Effect of Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid and Omeprazole: the ERY-PAO Study.Obesity surgery · 2016Trial
- The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors.The American journal of psychiatry · 2012Trial
- Navigating liver transplantation after malabsorptive bariatric surgery: A new risk of rejection.World journal of transplantation · 2026Article
- Considerations in Liver Transplant Recipients Having Prior Roux-en-Y Gastric Bypass.Transplantation direct · 2026Article
- Is Oral Semaglutide a Good Fit for Patients After Metabolic Bariatric Surgery? A Biopharmaceutical Mechanistic Perspective.Pharmaceutics · 2026Article
- Kidney transplantation in obese Black patients: Strategies to improve access and outcomes.World journal of nephrology · 2026Review
- Impact of Bariatric Surgery on Post-Transplant Outcomes in Solid Organ Recipients: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Increased risk of rejection in liver transplant recipients with a history of malabsorptive bariatric surgery.World journal of transplantation · 2025Article
- Association between bariatric surgery after kidney transplantation and graft and survival outcomes.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025Article
- Evaluating the safety of bariatric surgery as a bridge to kidney transplant: a retrospective cohort study.Surgical endoscopy · 2024Article
- Molecular Mechanisms Affecting Statin Pharmacokinetics after Bariatric Surgery.International journal of molecular sciences · 2024Review
- Obesity, organ failure, and transplantation: a review of the role of metabolic and bariatric surgery in transplant candidates and recipients.Surgical endoscopy · 2024Review
- Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study).Journal of clinical trials · 2024Article
- Timing Considerations for Sleeve Gastrectomy in Kidney Transplant Patients: A Single Center Evaluation.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Management and Risks Before, During, and After Liver Transplant in Individuals With Obesity.Gastroenterology & hepatology · 2023Article
- Bariatric Surgery in Kidney Transplant Candidates and Recipients: Experience at an Asian Center.Journal of obesity & metabolic syndrome · 2022Article
- Outcomes of Bariatric Surgery Before, During, and After Solid Organ Transplantation.Obesity surgery · 2022Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPromising data regarding the safety and efficacy of gastric bypass surgery (GBS) as an option to address obesity in the transplant population are emerging. The data lack on how GBS may alter the pharmacokinetics (PK) of modern immunosuppression. The objective of this study was to describe the alterations in the PK of modern immunosuppressants and the GBS population.
methodsData are presented on six subjects who participated in this trial--four were on dialysis and two were renal transplant recipients. Dialysis-dependent bypass subjects received a single dose of 6 mg of sirolimus, two 4-mg doses of tacrolimus and two 1000-mg doses of mycophenolate mofetil (MMF) over the 24-h study period. Transplant recipients continued their current regimen. Maximum plasma concentration (C(max)), time to reach the maximum plasma concentration (T(max)) and the area under the plasma concentration vs. time curve (AUC(0-12) and AUC(0-infinity) where appropriate) were calculated for tacrolimus, sirolimus, mycophenolic acid (MPA) and mycophenolic acid glucuronide (MPAG).
resultsSignificant inter-patient variability in the C(max), T(max) and AUC of tacrolimus, sirolimus MPA and MPAG was observed. A notable difference in the AUC:dose ratio for tacrolimus was seen when comparing data with published data in the non-bypass population. Similar differences in PK were seen with sirolimus, MPA and MPAG.
conclusionsWhen comparing the PK of sirolimus, tacrolimus, MPA and MPAG to published PK data in the non-bypass population, significant differences are observed. It is likely that transplant recipients with GBS would need higher doses of tacrolimus, sirolimus and MMF to provide similar exposure to a non-bypass patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.